Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

First X-Linked Mental Retardation Diagnostic Panel Developed

By LabMedica International staff writers
Posted on 27 Apr 2010
A range of genetic tests has been developed that are expected to pinpoint the cause of intellectual disability and X-linked mental retardation (XLMR).

This panel marks the first time next-generation sequencing technology, combined with microarrays, Sanger sequencing, and traditional fragile-X testing, is being made clinically available to address this disorder, giving physicians a full range of reflex options to suit the needs of their patients.

The Ambry Genetics' (Aliso Viejo, CA, USA) XLMR SuperPANEL spans all levels of genetic resolution, from genome-wide scan through focused study of the X chromosome to base-pair analysis of approximately 90 specific target genes. More...
Components include the XLMR Array Plus, the XLMR Next Gen Sequencing Panel, and individual sequencing tests including Fragile X. Testing can be customized for individual patients. The Sequencing Panel uses new and innovative technologies, including RainDance Technologies' (Lexington, MA, USA) RDT 1000 system for sequence enrichment with the Illumina genome analyzer IIx. Ambry has been an Illumina-certified service provider for research services since 2007.

"I'm very excited about the various technologies we applied to this suite of tests, and that we can develop similar tests for other complex disease states,” said Anja Kammesheidt, chief scientific officer at Ambry Genetics. "The new technologies create an important paradigm shift and allow us to comprehensively investigate complex genetic disorders in the same way monogenic disorders have been diagnosed for years.”

"Ambry Genetics is ideally suited to bring multigenic assays into the marketplace,” said Charles Dunlop, chief executive officer. "We've not only been performing services on these platforms for years with a very good understanding of the nuances of these technologies, but we also have over a decade of experience launching high information-content sequencing tests. We know how to deal with the interpretation issues that arise at the patient level, and our company is geared towards helping physicians with this type of information.”

Intellectual disability (also called mental retardation) is a lifelong impairment of cognitive and adaptive skills affecting approximately 2% - 3% of the general population. For approximately half of patients who have undergone extensive traditional evaluations, the cause remains unknown. About 10% - 15% of intellectual disability is attributed to genetic defects of the X chromosome and is called XLMR. The disorder affects as many as 1/1,000 to 1/600 males plus a significant number of females.

Ambry Genetics specializes in the application of new technologies to molecular diagnostics and genetics research.

Related Links:
Ambry Genetics


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.